Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Eur Urol. 2011 Apr;59(4):619-28. doi: 10.1016/j.eururo.2010.11.043. Epub 2010 Dec 8.
Animal models are instrumental in understanding disease pathophysiology and mechanisms of therapy action and resistance in vivo.
To establish and characterize a panel of mouse models of renal cell carcinoma (RCC) derived from patients undergoing radical nephrectomy.
DESIGN, SETTING, AND PARTICIPANTS: In vivo and in vitro animal experiments.
Tumor tissues obtained during surgery were implanted into the subcutaneous space of female BALB/c nude mice and serially passaged into new mice. Tumors were characterized by histology, short tandem repeat (STR) fingerprinting, von Hippel-Lindau (VHL) gene sequencing, and single nucleotide polymorphism (SNP) analysis. Tumor-bearing mice were treated with sunitinib or everolimus. Primary cell cultures were derived from patient tumors and transfected with a lentivirus carrying the luciferase gene. Four subcutaneous xenograft mouse models were developed, representing papillary type 1, papillary type 2, clear cell, and clear cell with sarcomatoid features RCC.
RCC mouse models were established from four patients with distinct histologies of RCC. Tumor growth was dependent on histologic type, the size of the implanted tumor chip, and the passage number. Mouse tumors accurately represented their respective original patient tumors, as STR fingerprints were matching, histology was comparable, and SNP profiles and VHL mutation status were conserved with multiple passages. Bioluminescence imaging results were commensurate with subcutaneous xenograft growth patterns. Mice treated with sunitinib and everolimus exhibited an initial response, followed by a later stage of resistance to these agents, which mimics the clinical observations in patients with RCC.
We developed four mouse xenograft models of RCC with clear-cell and papillary histologies, with stable histologic and molecular characteristics. These models can be used to understand the basic biology of RCC as well as response and resistance to therapy.
动物模型在理解疾病的病理生理学以及体内治疗作用和耐药机制方面具有重要作用。
建立并鉴定一组源自接受根治性肾切除术的患者的肾细胞癌(RCC)小鼠模型。
设计、设置和参与者:体内和体外动物实验。
手术中获得的肿瘤组织被植入雌性 BALB/c 裸鼠的皮下空间,并连续传代到新的小鼠中。通过组织学、短串联重复(STR)指纹图谱、von Hippel-Lindau(VHL)基因测序和单核苷酸多态性(SNP)分析对肿瘤进行特征描述。荷瘤小鼠接受舒尼替尼或依维莫司治疗。从患者肿瘤中分离出原代细胞,并转染携带荧光素酶基因的慢病毒。建立了 4 种皮下异种移植小鼠模型,代表 1 型乳头状、2 型乳头状、透明细胞和伴有肉瘤样特征的透明细胞 RCC。
从 4 名具有不同组织学特征的 RCC 患者中建立了 RCC 小鼠模型。肿瘤生长依赖于组织学类型、植入的肿瘤芯片大小和传代数。小鼠肿瘤准确地代表了各自的原始患者肿瘤,STR 指纹图谱匹配,组织学相似,并且 SNP 图谱和 VHL 突变状态在多次传代后得以保持。生物发光成像结果与皮下异种移植的生长模式相符。接受舒尼替尼和依维莫司治疗的小鼠表现出初始反应,随后对这些药物产生耐药,这与 RCC 患者的临床观察一致。
我们开发了 4 种具有透明细胞和乳头状组织学特征的 RCC 小鼠异种移植模型,具有稳定的组织学和分子特征。这些模型可用于了解 RCC 的基础生物学以及对治疗的反应和耐药性。